(4-(azidomethyl)phenoxy)(tert-butyl)dimethylsilane | 1391092-01-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (4-(azidomethyl)phenoxy)(tert-butyl)dimethylsilane
• 英文别名: [4-(azidomethyl)phenoxy]-tert-butyl-dimethylsilane
• CAS: 1391092-01-5
• 化学式: C₁₃H₂₁N₃OSi
• 分子量: 263.415
• InChiKey: ALBJCJKDKKWYKV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.88
• 重原子数：
  18.0
• 可旋转键数：
  4.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  57.99
• 氢给体数：
  0.0
• 氢受体数：
  2.0

反应信息

• 作为反应物：
  描述：

  (4-(azidomethyl)phenoxy)(tert-butyl)dimethylsilane 在 C₅₄H₄₄N₂O₄Ru₂ 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 生成
  参考文献：
  名称：

  苄基叠氮化物和芳基叠氮化物之间的氧化还原反应：芳基腈和苯胺的协同合成†

  摘要：

  描述了苄基叠氮化物和芳基叠氮化物之间独特且新颖的反应，其以光活化的二钌配合物催化同时合成芳基腈和苯胺。N-未取代的亚胺（NH-亚胺）首先由叠氮化物生成，然后是NH-亚胺与芳基叠氮化物之间的氢转移反应。在中性和温和的反应条件下合成了多种芳基腈和苯胺。

  DOI：

  10.1039/c6ob02615j
• 作为产物：
  描述：

  叔丁基二甲基氯硅烷 在 咪唑 、 sodium tetrahydroborate 、 乙醇 、 偶氮二甲酸二异丙酯 、 叠氮磷酸二苯酯 、 三苯基膦 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 33.5h， 生成 (4-(azidomethyl)phenoxy)(tert-butyl)dimethylsilane
  参考文献：
  名称：

  环状二芳基 λ3-溴烷：通过环加成反应快速获得分子复杂性

  摘要：

  联芳基化合物在有机合成中有着广泛的应用。然而，由于制备具有挑战性，顺序多取代的联芳基化合物尚未得到充分开发。在此，我们报道了通过环状二芳基 λ 3 -溴的周环反应合成不对称的 2,3,2',3',4-取代的联芳基。官能团耐受性和原子经济性允许在单个反应步骤中获得分子复杂性。连续流动协议已被设计用于放大反应，而后功能化已开发利用剩余的 Br 原子。

  DOI：

  10.1021/acs.orglett.1c03278

文献信息

• Electrophotochemical Decarboxylative Azidation of Aliphatic Carboxylic Acids
  作者：Yukang Wang、Liubo Li、Niankai Fu

  DOI：10.1021/acscatal.2c02934

  日期：2022.9.2

  metal-catalyzed strategy that harnesses the power of light and electricity for radical decarboxylative functionalization of aliphatic carboxylic acids. This environmentally friendly protocol smoothly converts a diverse array of aliphatic carboxylic acids into the corresponding alkyl azides without using chemical oxidants or azido-group transfer reagents. The visible light energy and electric energy can be applied

  我们报告了一种电光化学金属催化策略，该策略利用光和电的力量对脂肪族羧酸进行自由基脱羧官能化。这种环保协议可将多种脂肪族羧酸顺利转化为相应的烷基叠氮化物，而无需使用化学氧化剂或叠氮基转移试剂。可见光能量和电能可以空间分离的方式与模块化电流池一起用于大规模合成。
• Synthesis and Biological Evaluation of Hapten‐Clicked Analogues of The Antigenic Peptide Melan‐A/MART‐1 _26(27L)‐35
  作者：Marion Tarbe、John J. Miles、Emily S. J. Edwards、Kim M. Miles、Andrew K. Sewell、Brian M. Baker、Stéphane Quideau

  DOI：10.1002/cmdc.202000038

  日期：2020.5.6

  AbstractA click‐chemistry‐based approach was implemented to prepare peptidomimetics designed in silico and made from aromatic azides and a propargylated GIGI‐mimicking platform derived from the altered Melan‐A/MART‐126(27L)‐35 antigenic peptide ELAGIGILTV. The CuI‐catalyzed Huisgen cycloaddition was carried out on solid support to generate rapidly a first series of peptidomimetics, which were evaluated for their capacity to dock at the interface between the major histocompatibility complex class‐I (MHC‐I) human leucocyte antigen (HLA)‐A2 and T‐cell receptors (TCRs). Despite being a weak HLA‐A2 ligand, one of these 11 first synthetic compounds bearing a p‐nitrobenzyl‐triazole side chain was recognized by the receptor proteins of Melan‐A/MART‐1‐specific T‐cells. After modification of the N and C termini of this agonist, which was intended to enhance HLA‐A2 binding, one of the resulting seven additional compounds triggered significant T‐cell responses. Thus, these results highlight the capacity of naturally circulating human TCRs that are specific for the native Melan‐A/MART‐126‐35 peptide to cross‐react with peptidomimetics bearing organic motifs structurally different from the native central amino acids.
• Synthesis, electrochemistry and anticancer activity of novel ferrocenyl phenols prepared via azide-alkyne 1,3-cycloaddition reaction
  作者：Damian Plażuk、Błażej Rychlik、Andrzej Błauż、Sławomir Domagała

  DOI：10.1016/j.jorganchem.2012.05.042

  日期：2012.9

  A series of monophenols and diphenols containing the ferrocene-C-triazolyl and ferrocene-N-triazolyl bond were prepared in a cycloaddition reaction of ethynylferrocene with aryl and benzyl azides and in a reaction of azidoferrocene with phenylacetylenes, respectively. The anticancer activity of the prepared compounds against hormone-dependent (MCF-7) and hormone-independent (HCC38) breast cancer cell lines was studied. The investigated compounds exhibited moderate anticancer activity against hormone-independent (IC50 similar to 15-48 mu M) cancer cell line and low activity against hormone-dependent cancer cell line (IC50 similar to 84-98 mu M). (C) 2012 Elsevier B. V. All rights reserved.